Navigation Links
FDA Extends Marketing Exclusivity for INOMAX®
Date:1/5/2011

CLINTON, N.J., Jan. 5, 2011 /PRNewswire/ -- Ikaria, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted INOMAX® (nitric oxide) for inhalation an additional six months of marketing exclusivity, known as "pediatric exclusivity."  The action extends exclusivity for INOMAX from January 2013 to July 2013. This decision was based on data submitted from three clinical trials of INOMAX in pre-term infants at risk for bronchopulmonary dysplasia (BPD), a serious respiratory condition resulting from lung injury.

Data from three large, multi-center, double-blind, placebo-controlled clinical trials examining the efficacy and safety of INOMAX in pre-term infants less than or equal to 34 weeks gestational age were submitted to the FDA.  Although the safety and tolerability of INOMAX has been shown in these trials, substantial evidence of efficacy has not been demonstrated. Therefore, Ikaria continues to study the efficacy of INOMAX for the prevention in BPD in pre-term infants through its Phase III clinical trial, which commenced in December 2009. INOMAX is not indicated for the prevention of BPD in pre-term infants.

INOMAX is indicated for the treatment of hypoxic respiratory failure, or HRF, in term and near-term (greater than 34 weeks) infants.  HRF occurs when the cells in the body are unable to receive enough oxygen, and is a life-threatening condition for newborns. INOMAX helps critically ill newborns breathe more effectively by dilating the blood vessels of the lungs, which improves oxygen uptake and maximizes oxygen supply to the tissues of the body. Use of INOMAX reduces the need for extracorporeal membrane oxygenation (ECMO), a highly-invasive and expensive surgical procedure in which an infant's blood is mechanically oxygenated by connecting the newborn to a heart-lung machine.

INOMAX is delivered as part of a comprehensive offering known as INOtherapy®.  In addition to INOMAX, INOtherapy includes use of Ikaria's proprietary, FDA-cleared drug-delivery system, all related disposable items, distribution, emergency delivery, technical and clinical assistance, quality maintenance, on-site hospital training, and 24/7/365 customer service.

About INOMAX®  

INOMAX® is a vasodilator, which, in conjunction with ventilator support and other appropriate agents, is indicated for the treatment of term and near-term (greater than 34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation.

INOMAX should not be used in the treatment of neonates known to be dependent on right-to-left shunting of blood. Abrupt discontinuation of INOMAX may lead to a worsening condition. Methemoglobinemia is a dose-dependent side effect of inhaled nitric oxide therapy. Nitrogen

dioxide (NO2) forms rapidly in gas mixtures containing nitric oxide and oxygen, and therefore may cause airway inflammation and damage. Methemoglobin, NO2, and FiO2 should be monitored during nitric oxide administration.  

Please see attached prescribing information.  For additional more information about INOMAX, please visit www.inomax.com.  

About Ikaria, Inc.

Ikaria, Inc. is a biotherapeutics company focused on developing and commercializing innovative therapeutics and interventions designed to address the significant unmet needs of critically ill patients. The company's lead product is INOtherapy®, an all-inclusive offering of drug product, services and technologies. INOMAX® (nitric oxide) for inhalation, the drug included in the INOtherapy offering, is the only FDA-approved drug for the treatment of hypoxic respiratory failure associated with pulmonary hypertension in term and near-term infants.  INOtherapy also is marketed in Puerto Rico, Canada, Australia, Mexico and Japan. Ikaria acquired the North American and Australian rights to LUCASSIN® (terlipressin), a potential treatment for hepatorenal syndrome Type 1, as well as the exclusive worldwide license to IK-5001, a potential treatment for preventing cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction. The company also has a number of investigational compounds in development. Ikaria is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI, and a manufacturing facility in Port Allen, LA. Please visit www.ikaria.com.


'/>"/>
SOURCE Ikaria, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
4. FDA Extends Review of Genasense(R) NDA Appeal in Chronic Lymphocytic Leukemia
5. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
6. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
7. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
8. Neurosciences Institute Discovers Drug Extends Stroke Treatment Time to 24 Hours, Repairs Brain Tissue
9. Lincare Holdings Inc. Extends Terms of Employment Agreements with Executive Officers
10. Applied Seals North America Extends Global Network With Addition of Distributor in Europe
11. Circassia Extends its Clinical-Stage Portfolio With Phase II Trials of T-Cell Vaccines Against House Dust Mite and Cat Allergies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... 11, 2017  Caris Life Sciences ® , a ... promise of precision medicine, today announced that St. Jude ... Oncology Alliance™ (POA) as its 17 th member. ... Jude Crosson Cancer Institute will help develop standards of ... tumor profiling, making cancer treatment more precise and effective. ...
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical ... innovative solutions for injectable drug administration, today shared the ... ID Adapter for improving the intradermal administration of polio ... Skin Vaccination Summit in May 2017 by Dr. ... Polio Department, World Health Organization (WHO), and recently published ...
(Date:10/4/2017)... -- According to the Centers for Disease Control and Prevention (CDC), influenza ... Care is helping communities across Massachusetts , ... no-cost* flu shots through the end of the month. *Some ... ... flu shot is by the end of October, according to the Centers ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Ellevate Network, ... in business to advocate for action towards gender equality at their inaugural Summit in ... around the globe, and reached a social audience of over 3 million. To watch ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a ... “The Journey: From the Mountains to the Mission Field” is the creation of published ... all ages and currently teaches a class of ladies at her church, which she ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, ... a medical article to the newly revamped Cosmetic Town journal section, ... hair transplant procedure known as Follicular Unit Extraction (FUE). , Dr. ...
(Date:10/12/2017)... ... 12, 2017 , ... Health Literacy Innovations (HLI), creator of ... and the Cancer Patient Education Network (CPEN), an independent professional organization that shares ... strategic alliance. , As CPEN’s strategic partner, HLI will help support CPEN ...
Breaking Medicine News(10 mins):